Comparison of lipid-modifying effects and risk of cardiovascular events between aliskirenumab and ezetimibe in the treatment of ultra-high-risk ASCVD
Objective To compare the effects of aliskirenzumab and ezetimibe treatment on lipid regulation and the risk of cardiovascular events in patients with ultra-high-risk atherosclerotic cardiovascular disease(ASCVD),respectively.Methods The study subjects were 200 ultra-high-risk ASCVD patients admitted to our hospital from February 2023 to February 2024,which were divided into the aliskirenumab group(100 cases)and the ezetimibe group(100 cases)according to the application of different medications,and both groups were treated for 6 months.Compare the clinical efficacy of patients in the two groups,before and after treatment,lipid levels,lipid metabolism levels,as well as the incidence of adverse reactions and cardiovascular adverse events.Results The clinical efficacy of the aliskirenumab group was 92.00%,which was higher than that of the ezetimibe group(82.00%),and the incidence of cardiovascular adverse events was 17.00%,which was significantly lower than that of the ezetimibe group(P＜0.05);the mean increase in high-density lipoprotein cholesterol(HDL-C)after treatment was higher in the aliskirenumab group,and the levels of triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC)and lipoprotein a(LPa)were lower in the aliskirenumab group(P＜0.05),and the differences in the incidence of adverse reactions and mortality rates of patients in the two groups were not statistical significance(P＞0.05).Conclusion Compared with ezetimibe,the treatment of ultra-high-risk atherosclerotic cardiovascular disease with aliskirenumab can effectively reduce patients'lipid levels,and the incidence of cardiovascular adverse events is lower,with good safety.
NETL
NSTL
万方数据
